Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Fulvestrant + Samuraciclib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Fulvestrant | Faslodex | ICI 182,780 | Hormone - Anti-estrogens 31 | Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
| Samuraciclib | CT 7001|CT7001|CT-7001|ICEC0942 | CDK7 Inhibitor 16 | Samuraciclib (ICEC0942) is an orally available and selective CDK7 inhibitor that prevents Cdk7 phosphorylation to induce cell cycle arrest and apoptosis (PMID: 29545334, PMID: 32150405). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05963984 | Phase II | Fulvestrant + Samuraciclib Fulvestrant | A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC) | Completed | USA | TUR | HUN | ESP | 1 |
| NCT03363893 | Phase Ib/II | Samuraciclib Fulvestrant + Samuraciclib | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | Completed | USA | GBR | 0 |